# Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions

Study · id `cardio:ct-nct01516723` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01516723](<https://clinicaltrials.gov/study/NCT01516723>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01516723

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.

## Technical summary

Registry record NCT01516723. Randomized; single masking; primary purpose treatment. Start 2012-02 (actual); primary completion 2016-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 330 participants (enrolled count; ClinicalTrials.gov record NCT01516723, source copy `cardio:ctgov-nct01516723-2026-08-18`, retrieved 2026-10-26)
- Started: 2012-02 (actual) (ClinicalTrials.gov record NCT01516723, source copy `cardio:ctgov-nct01516723-2026-08-18`, retrieved 2026-10-26)
- Primary completion: 2016-02 (actual) (ClinicalTrials.gov record NCT01516723, source copy `cardio:ctgov-nct01516723-2026-08-18`, retrieved 2026-10-26)
- Completion: 2020-12-31 (actual) (ClinicalTrials.gov record NCT01516723, source copy `cardio:ctgov-nct01516723-2026-08-18`, retrieved 2026-10-26)
- Countries: Belgium; Netherlands (ClinicalTrials.gov record NCT01516723, source copy `cardio:ctgov-nct01516723-2026-08-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01516723-2026-08-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
- Acronym: PRISON-IV
- Condition: Coronary Artery Disease
- Condition: Coronary Disease
- Condition: Coronary Stenosis
- Intervention (Device): Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
- Lead sponsor: R&D Cardiologie
- Lead sponsor class: OTHER
- Collaborator: Biotronik SE & Co. KG
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: R&D Cardiologie (`cardio:org-r-d-cardiologie`)
- Registry lists this organization as a collaborator: Biotronik SE & Co. KG (`cardio:org-biotronik-se-co-kg`)

## Provenance

Content hash: d99d1901c700ec60cea53cfb5edf5d235a1948002aa9dca4fd88a05226cb6a7a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
